Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Log in

Molecular epidemiology of tuberculosis in the Kyrgyz Republic

https://doi.org/10.51350/zdravkg2022621186
Molecular epidemiology of tuberculosis in the Kyrgyz Republic
Полный текст Full text Толук текст  

PDF (RUS)

PDF (RUS)

PDF (RUS)
Abstract About the authors References

Abstract

Introduction. According to the World Health Organization, the Kyrgyz Republic is among the 18 countries with a high prevalence of multidrug-resistant tuberculosis. The molecular epidemiology of tuberculosis infection, including genetic diversity, markers of molecular drug resistance, and transmission routes of Mycobacterium tuberculosis complex strains in the Kyrgyz Republic, remain poorly understood. Whole genome sequencing (WGS) has been used to determine the molecular genetic structure of the strains circulating in the country. Purpose of the study. The purpose of the study was to describe the molecular genetic characteristics of strains of the Mycobacterium tuberculosis complex based on the whole genome sequensing. Materials and methods.Whole genome sequencing was carried out at the National Reference Laboratory of the National Center for Phthysiology under the supervision of the SNRL, Borstel, Germany. 475 MTBС isolates were tested in 2018 and 2019. Sequencing was performed according to the manufacturer's instructions on the MySeq platform, Illumina, USA. The MTBSeq protocol was used for comparative genomic analysis and the online tools “EvolView and PhyResSe” to perform graphical representation and screen for mutations mediating resistance to antituberculous drugs. Stata/IC version 16.1 was used for statistical analysis.Results. Using WGS, showed that the MTBC population structure in the Kyrgyz Republic mainly consists of three phylogenetic lineages (L). These lines are L2 (Beijing), L3 (Delhi/CAS) and L4 (Euro-American) as classified by Coll, Mc- Nerney and Niemann, Merker. The L2 strains were predominant (74.1%, 352/475), while the L3 and L4 strains accounted for 0.8% (4/475) and 25.1% (119/475), respectively. Next, we classified the L2 and L4 strains into several MTBC sublineages. The Beijing Central Asia (n=225), Beijing Central Asia outbreak (n=75) and Beijing Europe/Russian W148 Outbreak (n=28) subline strains are the most common strains compared to the other L2 subline strains and the L4 subline strains. Conclusions. Using WGS, have shown that pulmonary tuberculosis in the Kyrgyz Republic is mainly caused by L2 (Beijing) strains. Drug resistance is also associated with L2 strains, highlighting the important role of L2 strains in the epidemiology of tuberculosis in the country. Overall, our results provide a better understanding of the molecular epidemiology of tuberculosis in the Kyrgyz Republic and require additional molecular epidemiological studies to elucidate the dynamics of tuberculosis in the country and, therefore, control it.

About the authors

Калмамбетова Гульмира Исмаиловна, к.м.н., зав. национальной референс лаборатории Национального Центра Фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кадыров Абдуллаат Саматович, д.м.н., профессор, директор Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика
Сыдыкова Мээрбубу Мисировна, лабораторный специалист национальной референс лаборатории Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика

Мойдунова Нестан Кубанычбековна, к.м.н., ассистент кафедры фтизиатрии КГМА им. И.К.Ахунбаева, Бишкек, Кыргызская Республика

Kalmambetova Gulmira Ismailovna, Ph.D., Head of the National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Kadyrov Abdullaat Samatovich, MD, Professor, Director of the National Center for Phthisiology at the Ministry of Health, Bishkek, Kyrgyz Republic

Sydykova Meerbubu Misirovna, laboratory specialist, National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Moidunova Nestan Kubanychbekovna, Ph.D., Assistant, Department of Phthisiology, KSMA named after I.K.Akhunbaeva, Bishkek, Kyrgyz Republic


Калмамбетова Гулмира Исмаиловна, медицина илимдеринин кандидаты,  Республикалык рефенс лаборатория Улуттук фтизиатрия борборунун болум башчысы, Бишкек, Кыргыз Республикасы

Кадыров Абдуллаат Саматович, медицина илимдеринин доктору,  Улуттук фтизиатрия борбору мудуру, Бишкек, Кыргыз Республикасы

Сыдыкова Мээрбубу Мисировна, лабораториялык адис, Республикалык рефенс лаборатория Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Мойдунова Нестан Кубанычбекова, медицина илимдеринин кандидаты,  И. К. Ахунбаева атындагы Кыргыз мамлекеттик медициналык академиясынын фтизиатрия кафедрасынын жардамчысы, Бишкек, Кыргыз Республикасы

 

References

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.

Keywords
tuberculosis , molecular genetic methods , whole genome sequencing , L2 strain (Beijing)
Для цитирования

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К. Молекулярная эпидемиология туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2, с.86- 91. https://dx.doi.org/10.51350/zdravkg2022621186
For citation

Kalmambetova G.I.,Kadyrov A.S.,Sydykova M.M.,Moidunova N.K. Molecular epidemiology of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 2, pp. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186
Цитата үчүн

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы. Кыргызстандын саламаттык сактоо 2022, no 2, б. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186
Authors Kalmanbetova G.I., Kadyrov A.S., Sydykova M.M., Moidunova N.K.
Link doi.org https://doi.org/10.51350/zdravkg2022621186
Pages 86-91
Keywords tuberculosis, molecular genetic methods, whole genome sequencing, L2 strain (Beijing)
Russian
Об авторах

Калмамбетова Гульмира Исмаиловна, к.м.н., зав. национальной референс лаборатории Национального Центра Фтизиатрии Министерства здравоохранения, Бишкек, Кыргызская Республика
Кадыров Абдуллаат Саматович, д.м.н., профессор, директор Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика
Сыдыкова Мээрбубу Мисировна, лабораторный специалист национальной референс лаборатории Национального центра фтизиатрии при Министерстве здравоохранения, Бишкек, Кыргызская Республика

Мойдунова Нестан Кубанычбековна, к.м.н., ассистент кафедры фтизиатрии КГМА им. И.К.Ахунбаева, Бишкек, Кыргызская Республика
Полный текст

PDF (RUS)
Список литературы

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.
Для цитирования

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К. Молекулярная эпидемиология туберкулеза в Кыргызской Республике. Здравоохранение Кыргызстана 2022, № 2, с.86- 91. https://dx.doi.org/10.51350/zdravkg2022621186
English
About authors

Kalmambetova Gulmira Ismailovna, Ph.D., Head of the National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Kadyrov Abdullaat Samatovich, MD, Professor, Director of the National Center for Phthisiology at the Ministry of Health, Bishkek, Kyrgyz Republic

Sydykova Meerbubu Misirovna, laboratory specialist, National Reference Laboratory of the National Center for Phthisiology of the Ministry of Health, Bishkek, Kyrgyz Republic
Moidunova Nestan Kubanychbekovna, Ph.D., Assistant, Department of Phthisiology, KSMA named after I.K.Akhunbaeva, Bishkek, Kyrgyz Republic
Full text

PDF (RUS)
References

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.
For citation

Kalmambetova G.I.,Kadyrov A.S.,Sydykova M.M.,Moidunova N.K. Molecular epidemiology of tuberculosis in the Kyrgyz Republic. Health care of Kyrgyzstan 2022, No. 2, pp. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186
Kyrgyz
Авторлор жөнүндө

Калмамбетова Гулмира Исмаиловна, медицина илимдеринин кандидаты,  Республикалык рефенс лаборатория Улуттук фтизиатрия борборунун болум башчысы, Бишкек, Кыргыз Республикасы

Кадыров Абдуллаат Саматович, медицина илимдеринин доктору,  Улуттук фтизиатрия борбору мудуру, Бишкек, Кыргыз Республикасы

Сыдыкова Мээрбубу Мисировна, лабораториялык адис, Республикалык рефенс лаборатория Улуттук фтизиатрия борбору, Бишкек, Кыргыз Республикасы

Мойдунова Нестан Кубанычбекова, медицина илимдеринин кандидаты,  И. К. Ахунбаева атындагы Кыргыз мамлекеттик медициналык академиясынын фтизиатрия кафедрасынын жардамчысы, Бишкек, Кыргыз Республикасы

 
Толук текст

PDF (RUS)
Шилтемелер

1. World Health Organization. Global Tuberculosis Report 2019. S.l.: WORLD HEALTH ORGANIZATION; 2019.
2. WHO European TB Monitoring and Surveillance Report 2019.
3. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. The Lancet. 2015 May; 385(9979):1799–801.
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Sep;5(9): a017863.

5. Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, et al. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru. Int J Tuberc Lung Dis. 2017;16(11):1538–43.
6. Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, et al. The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia. PLOS ONE. 2016;13.
7. World Health Organization. Tuberculosis Country profiles: Kyrgyzstan [Internet]. 2019 [cited 2020 Jul 23]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/_inputs_&lan=%22EN%22&iso2=%22KG%22&main_tabs=%22est_tab%22.
8. The World Bank. The World Bank in the Kyrgyz Republic [Internet]. World Bank. [cited 2020 Apr 22]. Available from:
https://www.worldbank.org/en/country/kyrgyzrepublic/overview.
9. Helmy M, Awad M, Mosa KA. Limited resources of genome sequencing in developing countries: Challenges and solutions. Appl Transl Genomics. 2016 Mar 10;9:15–9.
10. World Health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide. 2018.
11. Ulmasov D.J,et al. Multidg-resistant tuberculosis in Uzbekistan: result is of a nationwide survey, 2010 to 2011.Euro Surveill. 2013;18(42):pin:20609.
12. Mokrousov l, et al.Penitentiary population of mycobacterium tuberculosis in Kyrgyzstan:exceptionally high prevalence of the Beijing genotype and its Russia-specific.subtype. Infect Genet. Evol. 2009,9(6):1400-5.
13. Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, et al. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med [Internet]2019 Apr 30 [cited 2020 Apr 23];16(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490892/.
14. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. JAMA J Am Med Assoc. 1998 Oct 7;280(13):1200-a-1200.
15. Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, et al. Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J [Internet]. 2021 Jan 1 [cited 2021 Feb 19];57(1). Available from: https://erj.ersjournals.com/content/57/1/2001796.
16. Mokrousov l, et al. Molecular snapshot of mycobacterium tuberculosis populations structure and drug resistance in Kyrgyzstan. Tuberculosis (Edinb). 2013.93(5):501-7.
17. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou E, et al. Phylogenetically informative mutations in genesimplicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020 Mar 6;12(1):27.
18. Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M. Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathog. 2018 Oct;14(10):e1007297.
19. Engstrom A., Antonenca U.,Kabyrov A.,Kalmambetova G et al.Population structure of drug-resistant Mycobacterium tuberculosis in Central Asia.BMC infectious Diseases.2019;19:908 https://doi.org/101186/s12879-019-4480-.
20. IIin A.I.,Kulmanov M.E.,Korotetskiyet I.S. et al. Complete Genome Sequence of Multidrug-Resistant Clinical Isolate Mycobacterium tuberculosis 187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1. Genome announcements, 2015, vol.3(6), e01272-15. CrossRef PubMed.
21. T. Phuong Quan et al. // Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping. // J. Clin. Microbiol. February 2018, 56:14 e01480-17; Accepted manuscript posted online 22 November 2017, DOI: 10.1128/JCM.01480-17.
22. Ustinova V. V., Smirnova T. G., Andreevskaya S. N., Andrievskaya I. Yu., Larionova E. E., Chernousova L. N. Genome sequencing of six clinical strains of nontuberculous mycobacteria. Tuberculosis and lung disease, № 12,2018
23. Kozhamkulov U., Kairov U., YerezhepovD., Akhmatova A. Whole-genome sequencing of clinical Mycobacterium tuberculosis isolates with different drug sensitivity profiles. June 2016 Biotechnology Theory and practice. DOI: 10.11134/bop.2.2016.2.
Цитата үчүн

Калмамбетова Г.И., Кадыров А.С., Сыдыкова М.М., Мойдунова Н.К.Кыргыз Республикасындагы кургак учуктун молекулярдык эпидемиологиясы. Кыргызстандын саламаттык сактоо 2022, no 2, б. 86-91. https://dx.doi.org/10.51350/zdravkg2022621186
Views: 4875
Copyright MAXXmarketing GmbH
JoomShopping Download & Support